^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Peripheral T-cell Lymphoma
    Drug:Campath (alemtuzumab) (CD52 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/22/2021
    Excerpt:
    Hepatosplenic T-Cell Lymphoma...Useful in certain circumstances...Alemtuzumab + pentostatin
    Secondary therapy:
    pentostatin
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Peripheral T-cell Lymphoma: Second-line or initial palliative intent therapy (no intention to transplant) and subsequent therapy...Other recommended regimens…Alemtuzumab